New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
10:02 EDTREN, MOV, ENBL, A, SFBS, RYAM, LDRH, EOX, TIF, PEGI, KW, DMND, NILE, ACTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) resumed with an Overweight at JPMorgan... Agilent (A) reinstated with a Neutral at Goldman... Blue Nile (NILE) initiated with a Market Perform at Barrington... Diamond Foods (DMND) initiated with an Outperform at Credit Suisse... Emerald Oil (EOX) initiated with a Buy at Brean Capital... Enable Midstream (ENBL) initiated with a Market Perform at Wells Fargo... Kennedy Wilson (KW) initiated with a Buy at Deutsche Bank... LDR Holding (LDRH) initiated with an Outperform at RBC Capital... Movado (MOV) initiated with an Outperform at Barrington... Pattern Energy (PEGI) initiated with a Buy at KeyBanc... Rayonier Advanced Materials (RYAM) initiated with an Outperform at RBC Capital... Resolute Energy (REN) initiated with a Neutral at Global Hunter... ServisFirst (SFBS) initiated with an Outperform at Raymond James... Tiffany (TIF) initiated with a Market Perform at Barrington.
News For ACT;NILE;A;DMND;EOX;ENBL;KW;LDRH;MOV;PEGI;RYAM;REN;TIF;SFBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
08:19 EDTEOXEmerald Oil downgraded to Neutral from Outperform at Macquarie
Subscribe for More Information
07:41 EDTEOXEmerald Oil downgraded to Neutral from Outperform at Macquarie
Subscribe for More Information
06:14 EDTACTAllergan price target raised to $245 from $210 at Citigroup
Subscribe for More Information
December 8, 2014
18:24 EDTDMNDOn The Fly: After Hours Movers
Subscribe for More Information
16:10 EDTDMNDDiamond Foods backs FY15 EPS view 90c-$1.10, consensus $1.03
16:09 EDTDMNDDiamond Foods reports Q1 EPS 28c, consensus 25c
Subscribe for More Information
15:19 EDTDMNDNotable companies reporting after market close
Subscribe for More Information
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTACTLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:00 EDTEOXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:32 EDTPEGIPattern Energy upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
07:40 EDTEOXMany E&P target prices lowered at SunTrust
Subscribe for More Information
07:23 EDTEOXEmerald Oil Oasis Petroleum downgraded to Neutral from Buy at SunTrust
Subscribe for More Information
07:16 EDTDMNDDiamond Foods December volatility elevated into Q1 and outlook
Diamond Foods December call option implied volatility is at 59, January is at 44, March is at 39; compared to its 26-week average of 38 according to Track Data, suggesting large near term price movement into the expected release of Q1 results today.
December 5, 2014
16:49 EDTACTAdvisory Committee recommends approval Of Actavis' ceftazidime-avibactam
Actavis announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections and complicated urinary tract infections caused by Gram-negative pathogens. The committee found the scientific and clinical evidence submitted by Cerexa, a wholly owned subsidiary of Actavis, adequately demonstrated the safety and efficacy of ceftazidime-avibactam in the treatment of the proposed cIAI and cUTI indications. The committee voted not to recommend approval of the combination for hospital-acquired bacterial pneumonia /ventilator-associated bacterial pneumonia and bacteremia.The Advisory Committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for ceftazidime-avibactam during the first quarter of 2015.
10:44 EDTAOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTEOXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:05 EDTDMNDDiamond Foods December volatility elevated into Q1 and outlook
Subscribe for More Information
08:50 EDTEOXWilliston Basin E&Ps downgraded at Iberia
Subscribe for More Information
08:02 EDTEOXEmerald Oil downgraded to Sector Perform from Outperform at Iberia
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use